Innate Pharma presents lacutamab Phase 3 development and approval roadmap
IPHA•IPHA•IPHA•IPHA•Innate Pharma initiated the lacutamab TELLOMAK-3 Phase 3 trial, with first patient enrollment expected in Q1 2027 and a potential US accelerated approval target in H1 2028. Sobi paid $75 million upfront, with additional milestones potentially totaling $465 million.
Innate Pharma initiated the TELLOMAK-3 Phase 3 trial of lacutamab in cutaneous T-cell lymphoma, with first patient enrollment expected in Q1 2027. The program targets potential US accelerated approval in Sézary syndrome in H1 2028, based on Phase 2 data. Sobi paid $75 million upfront for the partnership, with additional option-related, regulatory and commercial milestones that could reach $465 million.
High-level data from monalizumab’s PACIFIC-9 Phase 3 trial are scheduled for the first half of 2027. Innate Pharma expects Phase 1 data for IPH4502 in the second half of 2026; preliminary objective responses have been observed in solid tumors.
